From Our Partners
Tuesday, June 28, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

DARPA INTERCEPT Program for Biodefense Countermeasures

by Global Biodefense Staff
April 11, 2016
DARPA Intercept Proposer's Day Conference

DARPA Intercept Proposer's Day ConferenceThe Defense Advanced Research Projects Agency’s Biological Technologies Office (BTO) is hosting a Proposers Day in advance of a planned Broad Agency Announcement (BAA) for the INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) program.

The goal of the INTERCEPT program is to explore and develop a new therapeutic platform to outpace fast-evolving viral pathogens, based upon virus-based therapeutic particles that interfere with viral infection and co-evolve with viral targets.

Current preventive and therapeutic platforms including vaccines and anti-virals are designed to treat viral pathogens in their circulating state or at the time of diagnosis. However, pathogens mutate and evolve over time, becoming resistant to static therapies.

The INTERCEPT program builds upon previously reported naturally occurring Defective Interfering Particles (DIPs), viral-derived particles with partially deleted genomes that lack essential genes for replication enzymes and capsid proteins. DIPs rely on the wildtype parent virus to replicate and mobilize, and consume critical wildtype resources, thus interfering with the infection process.

Performers within the INTERCEPT program will aim to engineer and optimize therapeutic versions of DIPs as Therapeutic Interfering Particles (TIPs) to stoichiometrically outcompete the parent virus for viral proteins, in the process reducing viral load within a patient and attenuating viral transmission. Preliminary modeling studies suggest that the viral chassis of TIPs will enable them to co-evolve and keep pace with the viral pathogen as it mutates, thereby addressing the ongoing challenges of viral escape and therapeutic obsolescence.

The INTERCEPT program aims to explore and demonstrate the potential of TIPs for use as therapeutic and preventive platforms for the long-term control, at the individual and the population levels, of a broad range of fast-evolving viruses.

To explore the TIP concept as a therapeutic platform that can keep pace with fast-evolving pathogens, INTERCEPT will address four fundamental questions:

  • Safety & Efficacy: Can TIPs be built that are safe and out-compete the pathogen?
  • Co-evolution capability: Can TIPs safely evolve and keep pace with evolving pathogens to control an infection long-term?
  • Efficacy across populations: Can TIPs provide population-wide protection and infectious disease control?
  • Generalizability: Can the TIP concept be extended across multiple viruses and for multiple acute and chronic infectious diseases?

DARPA anticipates that INTERCEPT will encompass a four-year program organized in two phases of 2 years duration each.  During the Phase 1 period, performer teams will establish proof of concept of TIPs safety, broad range efficacy, and initial TIP-pathogen co-evolution using in vitro and in vivo models of viral infection, as well as mathematical models of TIP-pathogen-host dynamics. Phase 2 period will focus on the validation of long-term TIP safety and efficacy, long-term co-evolution studies, and TIP co-transmission dynamics for population-scale disease control.

The Proposers Day will be held on Friday, April 29, 2016 (UPDATE: the event has been rescheduled and will now take place April 28) in Arlington, VA. A webcast of the meeting will be broadcast for those who would like to participate remotely. Advance registration is required for both the physical meeting and the webcast. Registrants will have the opportunity to participate in an oral presentation that can be scheduled upon registration. Registration closes on Friday, April 22, 2016.

From Our Partners
Tags: BAADARPAEvents

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC